Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 27, 2019

View Archived Issues

Staph toxins' DARC arts: Targeting blood vessels

Alternative energy for metabolic brain disorder

H3 Biomedicine publishes preclinical pharmacokinetics and metabolism data on H3B-6545

Imbrium Therapeutics and TetraGenetics collaborate to develop novel biologic therapeutics for pain

TG Therapeutics initiates first-in-human study of its anti-CD47/CD19 bispecific antibody TG-1801

Acetylation by aspirin can attenuate autoimmunity

LY-3295668 demonstrates efficacy in RB1mut cancer models

Eribulin liposomal formulation well tolerated in patients with solid tumors

Nicotinamide N-methyltransferase inhibitor enhances aged muscle regeneration

Prion protein-binding monoclonal antibodies synthesized at New York University

Northwestern University presents beta-glucocerebrosidase activators

Bristol-Myers Squibb discovers sphingosine 1-phosphate receptor 1 agonists

New PD-1/PD-L1 interaction inhibitors patented by ChemoCentryx

Southeast University describes antibodies targeting the HPV16 E6 oncoprotein

New generation of SARDs for the treatment of advanced prostate cancer

Targeting DEFA1/DEFA3 ameliorates sepsis severity in mice

Alkermes begins ARTISTRY 2 study of subcutaneous ALKS-4230 in advanced solid tumors

Grants to support evaluation of Radspherin in colorectal cancer

Immatics Biotechnologies and Roche to test IMA-101 plus Tecentriq in cancer

FunPep gains Australian clearance for phase I/IIa study of FPP-003

MHRA clears Nuformix to begin human pharmacokinetic studies with NXP-001

Immunic initiates phase II study of IMU-838 for relapsing-remitting MS

Eidos initiates pivotal phase III study of AG-10 in ATTR-CM

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...